delayed cerebral ischemia; and 3) whether plasma ET is elevated in patients who develop cerebral vasospasm after SAH.
Materials and Methods

Monitoring of Patients
Thirteen patients with an aneurysmal SAH evidenced by blood clots in the basal cisterns on computerized tomography (CT) scanning were admitted to the neurological-neurosurgical intensive care unit at St. Mary's Hospital, Mayo Medical Center. All patients were admitted within 24 hours after ictus and studied for a minimum of 6 days. During the study, fluid balance and Swan-Ganz catheter parameters, if available, were recorded daily. All patients were graded using the World Federation of Neurological Surgeons (WFNS) grading system. 2 Transcranial Doppler (TCD) studies were performed at baseline and at regular intervals. Cerebral angiographic studies were performed in patients who deteriorated as a result of cerebral vasospasm despite maximum medical management (hypervolemic and hypertensive therapy).
Phlebotomy was performed in each patient twice daily (morning and afternoon). Blood samples were collected in chilled plastic tubes containing 7.5 mg potassium ethylenediamine tetraacetic acid (EDTA). Samples were immediately separated by centrifugation at 2500 rpm; 1-ml aliquots were stored at Ϫ20˚C and assayed after samples of all patients' blood had been collected. All patients received a minimum of 2 to 3 L of 0.9% NaCl with regular infusions of 250 ml of 5% albumen, particularly when large amounts of cisternal blood were present on admission CT scanning. All patients received an oral course of nimodipine for cerebral vasospasm prophylaxis.
Various Radioimmunoassays
We determined the circulating plasma concentration of human ANP with a newly developed, sensitive, nonequilibrium radioimmunoassay (RIA) for human ␣-ANP. The synthetic peptide of human ␣-ANP was used to prepare the standard and tracer. We labeled human ␣-ANP with Na 125 I using the Iodogen procedure. 9, 16 The crude, labeled peptide was purified first on a P-2 column and then by means of high-performance liquid chromatography on a C18 column. For the RIA, we first incubated rabbit antiserum to human ␣-ANP in the presence of the standard or sample for 24 hours and then added the labeled ANP for an additional 16 hours of incubation, both at 4˚C. Free and bound fractions of human ␣-ANP were separated by precipitation with goat antiserum to rabbit immunoglobulin G (second antibody); the incubation period with the second antibody was 30 minutes. The sensitivity of this assay is 3 pg/ml. Total binding is 35%, and the 50% displacement point on a standard curve is 28 pg.
Before the RIA, we used C18 cartridges to extract ANP from the plasma and to remove impurities. The eluted ANP was dried and reconstituted for the RIA. The recovery of the extraction procedure was 81 Ϯ 2% (mean standard error of the mean) as determined by addition of synthetic ANP to plasma. Inter-and intraassay variations were 9% and 6%, respectively.
Plasma BNP was determined using a specific RIA. One milliliter of plasma supernatant was preacidified and extracted on C8 cartridges and eluted with 1% trifluoroacetic acid/95% methanol. Concentrated eluates were then assayed using a BNP RIA kit. Samples or standards were incubated for 24 hours at 4˚C with 100 l of antibody raised against human BNP. The 125 I-labeled BNP (100 l) was added and incubated another 24 hours at 4˚C. Free and bound fractions were separated by addition of a second antibody and centrifuged, after which the pellet was counted. The minimum detectable concentration for the assay is 0.5 pg/tube. Recovery is 75 Ϯ 11%; inter-and intraassay variabilities are 12% and 10%, respectively. The crossreactivity of the BNP assay to other structurally related peptides was determined by the addition of synthetic ANP-28 in concentrations ranging from 0.5 to 500 pg/tube. There was no detectable immunoreactivity to ANP, demonstrating a crossreactivity of less than 1%. In addition, synthetic BNP-32 was added to the ANP assay in concentrations ranging from 0.5 to 500 pg/tube with no detectable immunoreactivity, demonstrating a crossreactivity of less than 1%.
The CNP immunoreactivity was determined using a double-antibody RIA. A specific antibody to human CNP-22 was used in the assay. Recovery of CNP was 72 Ϯ 6% as determined by addition of synthetic CNP to plasma. The lower limit of detection was 2 pg/tube. Intraassay variability was determined to be 5.2%. Crossreactivity of the CNP-22 antibody with CNP-53 was established by addition of synthetic CNP-53 to the CNP-22 assay at concentrations ranging from 2 to 500 pg/tube. The crossreactivity was determined to be 97 Ϯ 6%. There is no reported crossreactivity between the specific CNP-22 antibody and ANP, BNP, or ET. This was verified by addition of synthetic ANP, BNP, and ET to the CNP assay at concentrations ranging from 0.5 to 500 pg/tube with no detectable immunoreactivity.
For measurement of ET by RIA, 1 ml plasma was applied to C8 cartridges that had been washed with 4 ml of methanol and 4 ml of water. After acidification with 0.5% trifluoroacetic acid, plasma was applied to the cartridges, which were then washed with 2 ml of physiological saline and 6 ml of water. Endothelin was eluted from the cartridges with 2 ml of 90% methanol in 1% trifluoroacetic acid. Samples were dried with a centrifugal vacuum concentrator. The eluted ET was dried and reconstituted for the RIA, which used antibody to ET-1. The recovery by the extraction procedure was 82 Ϯ 11%, as determined by addition of synthetic ET-1 to plasma. Interassay and intraassay variations were 12% and 10%, respectively. The minimum level of detection for this assay is 0.5 pg/tube. The crossreactivity for this assay was 100% with ET-2 and 38% with pro-ET. Additional details on the methodology of the RIAs have been published previously.
9,16
Sources of Supplies and Equipment
Peninsula Laboratory, Inc. (Belmont, CA) provided the synthetic peptide of human ␣-ANP and the rabbit antiserum to human ␣-ANP (RAS 8798); the BNP RIA kit; synthetic ANP, BNP, and ET; synthetic ANP-28, BNP-32, and CNP-53; and the antibody to human CNP-22. Amersham International (Amersham, England) provided the antibody to ET-1. Bio-Rad (Hercules, CA) provided the P-2 column, and the Bond Elut cartridges used in the RIAs were obtained from Varian (Harbor City, CA).
Results
Clinical Features
Thirteen patients with aneurysmal SAH were evaluated in the neurological-neurosurgical intensive care unit. The age of the patients ranged from 39 to 73 years (median 56 years). There were eight patients with WFNS Grade I, two patients with WFNS Grade II, and three patients with WFNS Grades III or IV SAH. Admission CT scans demonstrated SAH in the basal cisterns in all patients, with additional presence of significant intraventricular hemorrhage in two patients (excluding patients with sedimentation in the posterior horns of the ventricular system). Acute hydrocephalus developed in three patients. Five patients had an anterior communicating artery aneurysm, four patients had a posterior communicating artery aneurysm, three patients had a middle cerebral artery aneurysm, and one patient had a carotid aneurysm. Within 48 hours after presentation, 11 patients underwent clipping of the aneurysm, and in two patients several platinum detachable coils were placed to obliterate the aneurysm.
Four patients developed delayed cerebral ischemia. Delayed cerebral ischemia was diagnosed on the basis of progressive drowsiness and either increased velocities on TCD ultrasonography or the presence of cerebral vasospasm on angiography. In three patients, no improvement was noted after hypertensive-hypervolemic treatment, and papaverine was infused intraarterially, which resulted in a significant decrease in the severity of cerebral vasospasm. Additional angioplasty of the M 1 segment of the middle cerebral artery was performed with success in one patient.
Plasma ANP, BNP, CNP, and ET Concentrations
The median admission values for ANP were 31.5 pg/ml (range 16.8-323 pg/ml); for BNP, 45.3 pg/ml (range 2.2-80.2 pg/ml); for CNP, 7.7 pg/ml (range Ͻ 2-20 pg/ml); and for ET, 11 pg/ml (range 6.5-25.1 pg/ml). The values for ANP and BNP were twofold higher than normal controls (normal ANP value 15 Ϯ 7 pg/ml; normal BNP value 12 Ϯ 9 pg/ml). Admission values for CNP and ET were not significantly different from controls (normal CNP value 5.2 Ϯ 3 pg/ml; normal ET value 7.2 Ϯ 4 pg/ml).
Interrelationship of Natriuretic System Peptides and Their Relationship With ET
The fluctuations in daily values of plasma ANP and plasma BNP are portrayed in Fig. 2 . The ANP and BNP profiles were similar in three patients (Cases 1, 3, and 8); however, plasma ANP and BNP changes appeared independent of each other in the remaining patients. No major fluctuations in ET (Ͼ 100% from baseline) were noted. In seven patients the plasma ET levels did not increase beyond 10 pg/ml during the days of measurement. In six patients only occasional samples showed an increase to a maximum of 25 pg/ml. No reciprocal profiles were found when ET was compared with ANP and BNP (data not shown).
Relationship Between the Natriuretic Peptide System and Fluid Balance
The cumulative fluid balance over 6 consecutive days ranged from Ϫ3.2 to 10.6 L (median 3.2 L). Of the 13 patients, three patients had a negative cumulative fluid balance: Ϫ2.1, Ϫ1.6, and Ϫ3.2 L, respectively. When a sensible loss of 750 ml daily was taken into account, eight of 13 patients had a negative fluid balance over 6 days.
Secondary increases (2nd and 3rd day) were noted over elevated baseline values in 11 patients for ANP, in 10 patients for BNP, and in three patients for CNP. (A secondary increase was defined as Ն 100% increase on two consecutive measurements.) No correlation between an increase in ANP, BNP, or CNP and a cumulative negative fluid balance was found, but increases in ANP or BNP were correlated with the development of a negative fluid balance the same day or 1 day thereafter in 10 patients. Frank hyponatremia (plasma sodium level of Յ 130 mmol/L) was found in only one patient. In five patients Swan-Ganz catheters were placed to monitor hypervolemic therapy. Pulmonary artery wedge pressure values ranged from 10 to 24 mm Hg in all instances.
Electrocardiographic abnormalities were documented in nine of 13 patients. In seven patients inverted T waves were found and in two patients a prolonged QT interval (normal QT interval is 0.41 seconds for women and 0.39 seconds for men). In two patients mild ventricular segmental hypokinesis was demonstrated on echocardiography, but without evidence of a left ventricular dysfunction, using pulmonary artery balloon catheter parameters.
Relationship Among Natriuretic System Peptides, ET, and Delayed Cerebral Ischemia
Four patients (Cases 1, 7, 12, and 13) (Fig. 2) developed delayed cerebral ischemia. In one additional patient (Case 3), abnormal TCD patterns were found but without any clinical manifestation of delayed cerebral ischemia. The plasma concentrations of the natriuretic peptides ANP and BNP, and of ET in these patients did not differ from the plasma concentrations in patients who did not develop cerebral ischemia (Fig. 2) . In four patients an elevation of CNP was noted (Ͼ 100% above baseline). Three of the four patients with delayed cerebral ischemia developed increases in CNP (the highest attained values were 17, 25, and 150 pg/ml) as opposed to one of the nine patients without delayed cerebral ischemia (highest value 145 pg/ml). However, this trend was not statistically significant (Fisher's exact test, p = 0.2). In one of the four patients with delayed cerebral ischemia, an increase in ET (maximum level 33 pg/ml) was observed, as opposed to increases in ET (maximum level 40 pg/ml) in five of nine patients without cerebral vasospasm.
Patient Outcome
In two patients a ventriculostomy was placed. Ten patients achieved an independent state or had a full recovery, two patients remained in a severely disabled state, and one patient died from massive bihemispheric infarction.
Discussion
To our knowledge, our study is the first to measure the entire natriuretic peptide system and its relationship with ET in patients with aneurysmal SAH. Several novel observations are apparent. First, plasma ANP and BNP increase above baseline value at ictus. These increases are mostly visible on the 2nd and 3rd day and although both peptides may increase, they do not seem to parallel each other in all instances. This indicates that these peptides seem to be differentially regulated; however, we cannot exclude an interaction. Second, the increases in ANP and BNP are associated with the development of a negative fluid balance on the same or the following day, suggesting that these natriuretic peptides are not a consequence of volume expansion and atrial stretch, but rather are implicated in natriuresis and diuresis. In fact, most of our patients exhibited a marginal fluid balance despite attention to fluid intake. Third, plasma ET levels were seldom elevated during SAH and no major fluctuations in these levels were noted during the period of observation. In addition, no reciprocal relationship between the ANP system and ET was found. This is in contrast to preliminary studies on plasma ET 13, 15 but in accordance with a more recent study of plasma ET concentrations in patients with aneurysmal SAH. 12 The role of ET in the pathogenesis of delayed cerebral ischemia seems established, and research is focusing on the development of ET receptor antagonists. 4, 21 However, measurement of plasma ET is not a clear reflection of its presence after SAH. Fourth, CNP was elevated in three patients, two of whom developed delayed cerebral vasospasm, although this trend was not statistically significant. This suggests that CNP has a regulatory vasodilator role. This conclusion, however, remains preliminary because of the small number of patients. A possible clinical application of this finding is that CNP or similar compounds may be capable of inhibiting the action of vasospastic substances. An observational study such as this cannot establish any causal link, but a recent study using CNP infusions found that CNP indeed can inhibit the vasoconstrictive effect of the renin-angiotensin system. 1 Brain natriuretic peptide clearly was elevated in all patients with aneurysmal SAH. What are the possible explanations for the apparent discrepancy between the results of our study and that of Isotani, et al.? 8 One explanation is that sampling in their study was performed every 2 to 4 days, raising the possibility that elevations in BNP may not have been detected. Another explanation may be a comparatively higher incidence of aneurysm in the anterior communicating artery complex with closer proximity to the hypothalamus in our study. Lesions in the hypothalamus may result in cardiac lesions with subsequent release of these peptides. Indeed, a previous study on digoxin immunoreactive substance, another recently identified natriuretic factor, in SAH confirmed such a relationship. 20 The mechanisms involved in the release of natriuretic peptides and recently discovered digoxinlike substances during SAH are not known. It would appear that an SAH produces the cardiac release of these natriuretic substances located in the atrium or ventricle. Cardiac release of these natriuretic substances does not necessarily correlate with electrocardiographic abnormalities pertaining to ventricular dysfunction, but this area needs further study. None of our patients had electrocardiographic abnormalities or significant cardiac arrhythmias and only two patients had hypokinesis of the left ventricular wall.
Although the chemistry of natriuretic peptides and their receptors has been outlined, the physiological regulation of these agents needs further refinement. However, plasma values as low as 50 pmol/L result in a significant increase in urine volume and sodium.
1 Therefore, the plasma values of ANP and BNP measured in our cohort of patients with aneurysmal SAH should account for the development of a negative fluid balance. The regulation and physiological properties of CNP remain largely speculative. Whether the increase in CNP, measured in some of our patients, results in a vasodilation is unknown. Nonetheless, it has been demonstrated that prolonged infusion of CNP significantly reduced lumen stenosis after injury to the arterial vessel wall. 18 On a practical level, our results demonstrate that plasma ANP and BNP are significantly elevated in aneurysmal SAH. The presence of two potent natriuretic substances should explain the overall difficulty of keeping these patients in adequate homeostasis. Hypervolemic therapy is often required to prevent volume contraction. Aggressive fluid management should begin promptly and may reduce the rates of mortality and morbidity from delayed cerebral ischemia. 5 Manipulation of the natriuretic peptide system and extension of the possible role of CNP in cerebral vasospasm warrants further investigation.
